Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Schlehuber, S. & Skerra, A. (2005) Anticalins in Drug Development. BioDrugs, 19(5), 279-288.
Key Takeaway: The article discusses the role of Anticalins in drug development, highlighting their potential applications. It provides insights into the mechanisms and advantages of using Anticalins in therapeutic contexts. However, the text lacks specific details or recent developments in the field.
Price reaction · baseline $22.05 (2025-06-20 close) · 11 other PVLA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita